


Coronavirus Disease 2019 (COVID-19)

October 28, 2020


Overview

- Epidemiologic update
- New monoclonal antibody treatments


Confirmed cases are increasing




Test positivity is increasing




Weekly Trends in COVID-like Illness



COVID-19 hospitalizations are increasing



COVID-19 deaths are fairly flat



Cases and hospitalizations increasing in both western and eastern Washington




Figure 2: Seven day rolling case counts (left panels), total tests (middle panels) and hospitalizations (right panels) for eastern Washington (top) and western Washington (bottom). Through October 15, recent daily case counts have increased rapidly in western Washington and increased at a slower rate in eastern Washington. Hospitalizations have increased in both regions.

Cases rising among most age groups




Figure 4. Seven day rolling average case counts by age group for eastern Washington (top) and western Washington (bottom) showing that increasing trends are widely distributed across age groups.

Source: <https://covid.idmod.org/#/ResearchandReports>

Summary

- COVID-19 transmission is increasing across the state, particularly in western Washington
- Recent growth in cases is widely distributed across the state
- Cases rising among most age groups
- Transmission occurring in multiple settings

Questions

- How concerned are you about your hospital capacity at this time?
- What are your criteria for cancelling or delaying non-urgent procedure? What should be the criteria for implementing more dramatic non-pharmaceutical interventions?

Monoclonal Antibody (mAb) Treatments

- Eli Lilly – Bamlanivimab (LY-CoV555)
 - Neutralizing IgG1 mAb directed against spike protein of SARS-CoV-2
 - Submitted EUA application to FDA for treatment of mild/moderate COVID-19 in high-risk patients
 - Agreed to supply 300,000 vials of antibody product to US government if EUA granted (\$1250 per vial)
 - Plans to make up to 1 million doses by the end of 2020
- Regeneron – REGN-COV2 (REGN10933 and REGN10987)
 - Two neutralizing mAbs directed against spike protein
 - Submitted EUA application to FDA for treatment of mild/moderate COVID-19 in high-risk patients

Eli Lilly – Bamlanivimab (LY-CoV555)

- Primate study (preprint):
<https://www.biorxiv.org/content/10.1101/2020.09.30.318972v1>
- Phase 2 trial results for LY-CoV555:
<https://www.nejm.org/doi/full/10.1056/NEJMoa2029849>
- Phase 2 press release for Ly-CoV555 and LY-CoV016:
<https://investor.lilly.com/news-releases/news-release-details/lilly-provides-comprehensive-update-progress-sars-cov-2>

Regeneron – REGN-COV2 (REGN10933 and REGN10987)

- Development:
<https://science.sciencemag.org/content/369/6506/1010>
- Animal studies:
<https://science.sciencemag.org/content/early/2020/10/14/science.abe2402>
- Phase 2/3 trial press release:
<https://investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates>

Federal Government Allocation Program

- Likely indications
 - High-risk, outpatients with mild/moderate illness (Need to administer by one hour infusion)
 - Will convene DMAC and other experts if EUA granted
- Allocation / distribution process
 - Initially, supplies will be limited
 - HHS will allocate to states based on HHS Protect data
 - DOH will approve orders
 - mAb products will be directly shipped to the end user
- Initially, no out-of-pocket costs for the medicine, but facilities may charge administration fee
- **Please contact Josh Russell (joshr@wsha.org) and Rebecca Baron (rebecca.baron@doh.wa.gov) if you want to receive and administer this therapeutic**



Washington State Department of Health is committed to providing customers with forms and publications in appropriate alternate formats. Requests can be made by calling 800-525-0127 or by email at civil.rights@doh.wa.gov. TTY users dial 711.